Loading Events

Register for Event

8:00 – 8:50 am

Registration and Coffee

8:50 – 9:00 am

Welcome and Introduction

9:00 – 9:40 am

State of the Art in Clinical Transporter DDI Evaluation
Maciej J. Zamek-Gliszczynski, Ph.D. (Senior Fellow and Director, GlaxoSmithKline)

9:40 – 10:20 am

Updates on FDA’s DDI Guidance for Transporter-Mediated DDIs: Considerations and Perspectives
Xinning Yang, Ph.D. (FDA)

10:20 – 10:35 am

Coffee Break

10:35 – 11:15 am

Comprehensive PBPK Modeling of Rifampicin for Predicting Complex Drug-Drug Interactions Considering Various Enzyme Inductions and OATP Inhibition/Induction Effects
Yuichi Sugiyama, Ph.D. (RIKEN)

11:15 – 11:55 am

Changes in Expression and Activity of Transporters in Disease: Do They Impact Pharmacokinetics and Toxicity of Drugs?
Raymond Evers, Ph.D. (Director, Merck)

11:55 – 1:00 pm


1:00 – 1:40 pm

Using DILIsym to Predict Hepatotoxicity Risk During Lead Optimization
Paul Michalski, Ph.D. (Fellow, GlaxoSmithKline)

1:40 – 2:20 pm

Prediction of DILI Risk: Beyond Mitochondrial Injury and BSEP Inhibition
Jack Uetrecht, M.D., Ph.D. (Professor of Pharmacy and Medicine, The University of Toronto)

2:20 – 2:40 pm

Coffee Break

2:40 – 3:20 pm

Factors Besides BSEP That Are Important for DILI: Nuclear Receptors, Enzymes and Other Transporters
Sandy Pang, Ph.D. (Professor of Pharmacy, The University of Toronto)

3:20 – 4:00 pm

Round Table Discussion
All Speakers

Share This Post, Choose Your Platform!